Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2025 16:01 ET | Source: I-Mab Biopharma

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) --...
June 26, 2025 06:30 ET | Source: I-Mab Biopharma

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study ...
June 18, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025

Virtual investor event planned for July 8th at 2:00pm EDT Event to follow presentation of new Phase 1b combination dose escalation data for givastomig (Claudin 18.2 x 4-1BB bispecific antibody) at...
June 12, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement

ROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology...
June 03, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series

ROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the...
May 20, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab to Present at Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the...
May 15, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update

Prioritization of givastomig as I-Mab’s lead program positions the Company for clinical progressNew givastomig combination data selected for mini-oral presentation at ESMO GI, being held July 2-5 in...
April 30, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025

ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the...
April 03, 2025 16:01 ET | Source: I-Mab Biopharma

I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in...
March 26, 2025 07:00 ET | Source: I-Mab Biopharma

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of...